Anatara Lifesciences Appendix 4E And Financial Report
Brisbane, Aug 30, 2016 - (ABN Newswire) - Anatara Lifesciences Ltd (ASX:ANR) today released its Appendix 4E for the period ending 30th June 2016.
Key points:
- Revenue significantly increased, resulting from Zoetis global Evaluation and Option to License Agreement for Detach(TM) and R&D activities
- Strong balance sheet - costs tightly controlled and the Company remains well funded
- Australian (APVMA) regulatory submission for Detach(TM) on track, with Australian launch expected in 2017
- With APVMA dossier almost completed, Anatara is moving forward with human gastrointestinal disease treatment development
Highlights from the period include:
- Increasing revenue from ordinary activities by 1,284% to $2.8m and reducing net loss after tax by 59% to $723k
- Establishing a global Evaluation and Option to License Agreement under which Zoetis will determine the potential for Detach(TM) to be used as a non-antibiotic, anti-infective product in food production animals
- Completing a second field trial with Detach(TM) in nearly 500 piglets, reducing the incidence and frequency of diarrhoea in weaner piglets
- Commencing a Target Animal Safety (TAS) study, which will be used in the registration dossier with the Australian Pesticides and Veterinary Medicines Association (APVMA)
- Formalising a collaboration agreement with the Pork CRC
- Expanding the patent position for Detach(TM) and
- Enhancing the experience and capability set across the Anatara team through additional key appointments
All activities undertaken during the period to 30th June 2016 positioned Anatara to submit its APVMA dossier for Australian regulatory approval of Detach(TM). It is expected that product launch will follow in 2017.
Chairman and CEO, Dr Mel Bridges said, "We are pleased to release our 2016 financial year results following what has been a very positive year for Anatara. Revenue is up as a result of a milestone payment under our exclusive global Evaluation and Option to License Agreement with Zoetis for our lead product, Detach(TM).
"With much of the work required for the APVMA submission completed, Anatara is now turning its attention to the application of its technology to target gastrointestinal diseases in humans. The company is undertaking a detailed review of the numerous gastrointestinal diseases, such as traveller's diarrhoea, where the Detach(TM) technology may offer significant benefits."
To view the full Report, please visit:
http://abnnewswire.net/lnk/10218N41
WEB: Appendix 4E and Financial Report
About: Anatara Lifesciences Ltd
Anatara Lifesciences (ASX:ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach(TM) is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called "super bugs" that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.
Contact:
Investor and Media inquiries:
Dr Mel Bridges
Chairman, Anatara Lifesciences
Key points:
- Revenue significantly increased, resulting from Zoetis global Evaluation and Option to License Agreement for Detach(TM) and R&D activities
- Strong balance sheet - costs tightly controlled and the Company remains well funded
- Australian (APVMA) regulatory submission for Detach(TM) on track, with Australian launch expected in 2017
- With APVMA dossier almost completed, Anatara is moving forward with human gastrointestinal disease treatment development
Highlights from the period include:
- Increasing revenue from ordinary activities by 1,284% to $2.8m and reducing net loss after tax by 59% to $723k
- Establishing a global Evaluation and Option to License Agreement under which Zoetis will determine the potential for Detach(TM) to be used as a non-antibiotic, anti-infective product in food production animals
- Completing a second field trial with Detach(TM) in nearly 500 piglets, reducing the incidence and frequency of diarrhoea in weaner piglets
- Commencing a Target Animal Safety (TAS) study, which will be used in the registration dossier with the Australian Pesticides and Veterinary Medicines Association (APVMA)
- Formalising a collaboration agreement with the Pork CRC
- Expanding the patent position for Detach(TM) and
- Enhancing the experience and capability set across the Anatara team through additional key appointments
All activities undertaken during the period to 30th June 2016 positioned Anatara to submit its APVMA dossier for Australian regulatory approval of Detach(TM). It is expected that product launch will follow in 2017.
Chairman and CEO, Dr Mel Bridges said, "We are pleased to release our 2016 financial year results following what has been a very positive year for Anatara. Revenue is up as a result of a milestone payment under our exclusive global Evaluation and Option to License Agreement with Zoetis for our lead product, Detach(TM).
"With much of the work required for the APVMA submission completed, Anatara is now turning its attention to the application of its technology to target gastrointestinal diseases in humans. The company is undertaking a detailed review of the numerous gastrointestinal diseases, such as traveller's diarrhoea, where the Detach(TM) technology may offer significant benefits."
To view the full Report, please visit:
http://abnnewswire.net/lnk/10218N41
WEB: Appendix 4E and Financial Report
About: Anatara Lifesciences Ltd
Anatara Lifesciences (ASX:ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach(TM) is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called "super bugs" that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.
Contact:
Investor and Media inquiries:
Dr Mel Bridges
Chairman, Anatara Lifesciences